Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease

Smoldering multiple myeloma (SMM) is usually followed expectantly without therapy. We conducted a phase 2 trial in 76 eligible patients with SMM, combining thalidomide (THAL, 200 mg/d) with monthly pamidronate. In the first 2 years, THAL dose reduction was required in 86% and drug was discontinued i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Barlogie, Bart, van Rhee, Frits, Shaughnessy, John D., Epstein, Joshua, Yaccoby, Shmuel, Pineda-Roman, Mauricio, Hollmig, Klaus, Alsayed, Yazan, Hoering, Antje, Szymonifka, Jackie, Anaissie, Elias, Petty, Nathan, Kumar, Naveen S., Srivastava, Geetika, Jenkins, Bonnie, Crowley, John, Zeldis, Jerome B.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2008
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2569167/
https://ncbi.nlm.nih.gov/pubmed/18669874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-06-164228
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados